- call +1-201-465-4211
- email sales@mrinsights.biz
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
Scope of the Report:
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
With the ever increasing new cancer cases across the globe and the conventional treatment methods unable to cope up with the challenges posed by the tumor and their immune response evading techniques, cancer immunotherapy brings a ray of hope. Cancer immunotherapy allows the host's immune cells to get sensitized with the tumor-associated antigens which in turn elicits B cell and T cell mediated immune response to target and eliminate tumor cells. This is the underlying principle of cancer immunotherapy.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion in 2025 is about 40%.
The worldwide market for Peptide Cancer Vaccine is expected to grow at a CAGR of roughly 23.1% over the next five years, will reach 780 million US$ in 2024, from 280 million US$ in 2019, according to a new study.
This report focuses on the Peptide Cancer Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
TapImmune
BrightPath Biotherapeutics
Ultimovacs
Sellas
Boston Biomedical
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Immatics
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Type I
Type II
Market Segment by Applications, can be divided into
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Peptide Cancer Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Peptide Cancer Vaccine, with price, sales, revenue and global market share of Peptide Cancer Vaccine in 2017 and 2018.
Chapter 3, the Peptide Cancer Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Peptide Cancer Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Peptide Cancer Vaccine market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Peptide Cancer Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Peptide Cancer Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Type I
1.2.2 Type II
1.3 Market Analysis by Applications
1.3.1 Breast Cancer
1.3.2 Lung Cancer
1.3.3 Melanoma
1.3.4 Prostate Cancer
1.3.5 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2014-2024)
1.4.1.2 Canada Market States and Outlook (2014-2024)
1.4.1.3 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2014-2024)
1.4.2.2 France Market States and Outlook (2014-2024)
1.4.2.3 UK Market States and Outlook (2014-2024)
1.4.2.4 Russia Market States and Outlook (2014-2024)
1.4.2.5 Italy Market States and Outlook (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2014-2024)
1.4.3.2 Japan Market States and Outlook (2014-2024)
1.4.3.3 Korea Market States and Outlook (2014-2024)
1.4.3.4 India Market States and Outlook (2014-2024)
1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2014-2024)
1.4.4.2 Egypt Market States and Outlook (2014-2024)
1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
1.4.4.4 South Africa Market States and Outlook (2014-2024)
1.4.4.5 Turkey Market States and Outlook (2014-2024)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 TapImmune
2.1.1 Business Overview
2.1.2 Peptide Cancer Vaccine Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.2 BrightPath Biotherapeutics
2.2.1 Business Overview
2.2.2 Peptide Cancer Vaccine Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.3 Ultimovacs
2.3.1 Business Overview
2.3.2 Peptide Cancer Vaccine Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.4 Sellas
2.4.1 Business Overview
2.4.2 Peptide Cancer Vaccine Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sellas Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.5 Boston Biomedical
2.5.1 Business Overview
2.5.2 Peptide Cancer Vaccine Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.6 Imugene
2.6.1 Business Overview
2.6.2 Peptide Cancer Vaccine Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Imugene Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.7 VAXON Biotech
2.7.1 Business Overview
2.7.2 Peptide Cancer Vaccine Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.8 Generex Biotechnology
2.8.1 Business Overview
2.8.2 Peptide Cancer Vaccine Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.9 ISA Pharmaceuticals
2.9.1 Business Overview
2.9.2 Peptide Cancer Vaccine Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.10 OncoTherapy Science
2.10.1 Business Overview
2.10.2 Peptide Cancer Vaccine Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.11 Immatics
2.11.1 Business Overview
2.11.2 Peptide Cancer Vaccine Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Immatics Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Peptide Cancer Vaccine Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
3.1 Global Peptide Cancer Vaccine Sales and Market Share by Manufacturer (2017-2018)
3.2 Global Peptide Cancer Vaccine Revenue and Market Share by Manufacturer (2017-2018)
3.3 Market Concentration Rate
3.3.1 Top 3 Peptide Cancer Vaccine Manufacturer Market Share in 2018
3.3.2 Top 6 Peptide Cancer Vaccine Manufacturer Market Share in 2018
3.4 Market Competition Trend
4 Global Peptide Cancer Vaccine Market Analysis by Regions
4.1 Global Peptide Cancer Vaccine Sales, Revenue and Market Share by Regions
4.1.1 Global Peptide Cancer Vaccine Sales and Market Share by Regions (2014-2019)
4.1.2 Global Peptide Cancer Vaccine Revenue and Market Share by Regions (2014-2019)
4.2 North America Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
4.3 Europe Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
4.4 Asia-Pacific Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
4.5 South America Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
4.6 Middle East and Africa Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
5 North America Peptide Cancer Vaccine by Country
5.1 North America Peptide Cancer Vaccine Sales, Revenue and Market Share by Country
5.1.1 North America Peptide Cancer Vaccine Sales and Market Share by Country (2014-2019)
5.1.2 North America Peptide Cancer Vaccine Revenue and Market Share by Country (2014-2019)
5.2 United States Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
5.3 Canada Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
5.4 Mexico Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
6 Europe Peptide Cancer Vaccine by Country
6.1 Europe Peptide Cancer Vaccine Sales, Revenue and Market Share by Country
6.1.1 Europe Peptide Cancer Vaccine Sales and Market Share by Country (2014-2019)
6.1.2 Europe Peptide Cancer Vaccine Revenue and Market Share by Country (2014-2019)
6.2 Germany Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
6.3 UK Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
6.4 France Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
6.5 Russia Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
6.6 Italy Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
7 Asia-Pacific Peptide Cancer Vaccine by Country
7.1 Asia-Pacific Peptide Cancer Vaccine Sales, Revenue and Market Share by Country
7.1.1 Asia-Pacific Peptide Cancer Vaccine Sales and Market Share by Country (2014-2019)
7.1.2 Asia-Pacific Peptide Cancer Vaccine Revenue and Market Share by Country (2014-2019)
7.2 China Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
7.3 Japan Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
7.4 Korea Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
7.5 India Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
7.6 Southeast Asia Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
8 South America Peptide Cancer Vaccine by Country
8.1 South America Peptide Cancer Vaccine Sales, Revenue and Market Share by Country
8.1.1 South America Peptide Cancer Vaccine Sales and Market Share by Country (2014-2019)
8.1.2 South America Peptide Cancer Vaccine Revenue and Market Share by Country (2014-2019)
8.2 Brazil Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
8.3 Argentina Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
8.4 Colombia Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
9 Middle East and Africa Peptide Cancer Vaccine by Countries
9.1 Middle East and Africa Peptide Cancer Vaccine Sales, Revenue and Market Share by Country
9.1.1 Middle East and Africa Peptide Cancer Vaccine Sales and Market Share by Country (2014-2019)
9.1.2 Middle East and Africa Peptide Cancer Vaccine Revenue and Market Share by Country (2014-2019)
9.2 Saudi Arabia Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
9.3 Turkey Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
9.4 Egypt Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
9.5 Nigeria Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
9.6 South Africa Peptide Cancer Vaccine Sales and Growth Rate (2014-2019)
10 Global Peptide Cancer Vaccine Market Segment by Type
10.1 Global Peptide Cancer Vaccine Sales, Revenue and Market Share by Type (2014-2019)
10.1.1 Global Peptide Cancer Vaccine Sales and Market Share by Type (2014-2019)
10.1.2 Global Peptide Cancer Vaccine Revenue and Market Share by Type (2014-2019)
10.2 Type I Sales Growth and Price
10.2.1 Global Type I Sales Growth (2014-2019)
10.2.2 Global Type I Price (2014-2019)
10.3 Type II Sales Growth and Price
10.3.1 Global Type II Sales Growth (2014-2019)
10.3.2 Global Type II Price (2014-2019)
11 Global Peptide Cancer Vaccine Market Segment by Application
11.1 Global Peptide Cancer Vaccine Sales Market Share by Application (2014-2019)
11.2 Breast Cancer Sales Growth (2014-2019)
11.3 Lung Cancer Sales Growth (2014-2019)
11.4 Melanoma Sales Growth (2014-2019)
11.5 Prostate Cancer Sales Growth (2014-2019)
11.6 Others Sales Growth (2014-2019)
12 Peptide Cancer Vaccine Market Forecast (2019-2024)
12.1 Global Peptide Cancer Vaccine Sales, Revenue and Growth Rate (2019-2024)
12.2 Peptide Cancer Vaccine Market Forecast by Regions (2019-2024)
12.2.1 North America Peptide Cancer Vaccine Market Forecast (2019-2024)
12.2.2 Europe Peptide Cancer Vaccine Market Forecast (2019-2024)
12.2.3 Asia-Pacific Peptide Cancer Vaccine Market Forecast (2019-2024)
12.2.4 South America Peptide Cancer Vaccine Market Forecast (2019-2024)
12.2.5 Middle East and Africa Peptide Cancer Vaccine Market Forecast (2019-2024)
12.3 Peptide Cancer Vaccine Market Forecast by Type (2019-2024)
12.3.1 Global Peptide Cancer Vaccine Sales Forecast by Type (2019-2024)
12.3.2 Global Peptide Cancer Vaccine Market Share Forecast by Type (2019-2024)
12.4 Peptide Cancer Vaccine Market Forecast by Application (2019-2024)
12.4.1 Global Peptide Cancer Vaccine Sales Forecast by Application (2019-2024)
12.4.2 Global Peptide Cancer Vaccine Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Peptide Cancer Vaccine Picture
Table Product Specifications of Peptide Cancer Vaccine
Figure Global Sales Market Share of Peptide Cancer Vaccine by Types in 2018
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
